RU2522002C2 - Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом - Google Patents

Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом Download PDF

Info

Publication number
RU2522002C2
RU2522002C2 RU2012102602/10A RU2012102602A RU2522002C2 RU 2522002 C2 RU2522002 C2 RU 2522002C2 RU 2012102602/10 A RU2012102602/10 A RU 2012102602/10A RU 2012102602 A RU2012102602 A RU 2012102602A RU 2522002 C2 RU2522002 C2 RU 2522002C2
Authority
RU
Russia
Prior art keywords
protein
binding
human
bispecific
region
Prior art date
Application number
RU2012102602/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2012102602A (ru
Inventor
Самьюэл ДЭВИС
Эрик СМИТ
Дуглас МАКДОНАЛД
Кара Луиз ОЛСОН
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42738900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2522002(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of RU2012102602A publication Critical patent/RU2012102602A/ru
Application granted granted Critical
Publication of RU2522002C2 publication Critical patent/RU2522002C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/088—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing other elements, e.g. B, Si, As
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2012102602/10A 2009-06-26 2010-06-25 Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом RU2522002C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22068709P 2009-06-26 2009-06-26
US61/220,687 2009-06-26
PCT/US2010/040028 WO2010151792A1 (en) 2009-06-26 2010-06-25 Readily isolated bispecific antibodies with native immunoglobulin format

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2014114172/10A Division RU2569157C2 (ru) 2009-06-26 2014-04-10 Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом

Publications (2)

Publication Number Publication Date
RU2012102602A RU2012102602A (ru) 2013-08-10
RU2522002C2 true RU2522002C2 (ru) 2014-07-10

Family

ID=42738900

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2012102602/10A RU2522002C2 (ru) 2009-06-26 2010-06-25 Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
RU2014114172/10A RU2569157C2 (ru) 2009-06-26 2014-04-10 Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
RU2015140911A RU2647758C2 (ru) 2009-06-26 2015-09-25 Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2014114172/10A RU2569157C2 (ru) 2009-06-26 2014-04-10 Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
RU2015140911A RU2647758C2 (ru) 2009-06-26 2015-09-25 Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом

Country Status (24)

Country Link
US (7) US8586713B2 (enExample)
EP (3) EP2445936A1 (enExample)
JP (6) JP5816170B2 (enExample)
KR (5) KR20120027055A (enExample)
CN (2) CN103833855A (enExample)
AU (2) AU2010265933B2 (enExample)
CA (1) CA2766220C (enExample)
CY (1) CY1124358T1 (enExample)
DK (1) DK2975051T3 (enExample)
ES (1) ES2865648T3 (enExample)
HR (1) HRP20210637T1 (enExample)
HU (1) HUE054257T2 (enExample)
IL (2) IL217000A0 (enExample)
LT (1) LT2975051T (enExample)
MX (5) MX384993B (enExample)
MY (4) MY199658A (enExample)
PL (1) PL2975051T3 (enExample)
PT (1) PT2975051T (enExample)
RU (3) RU2522002C2 (enExample)
SG (1) SG176868A1 (enExample)
SI (1) SI2975051T1 (enExample)
SM (1) SMT202100250T1 (enExample)
TW (1) TWI507525B (enExample)
WO (1) WO2010151792A1 (enExample)

Families Citing this family (655)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI507525B (zh) * 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
BR112012004697B8 (pt) * 2009-09-01 2021-05-25 Genentech Inc método para purificar um polipeptídeo compreendendo uma região ch2/ch3
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
AU2010336277B2 (en) * 2009-12-25 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Polypeptide modification method for purifying polypeptide multimers
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) * 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
PT2560993T (pt) * 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
EP2598530A2 (en) 2010-07-29 2013-06-05 Xencor, Inc. Antibodies with modified isoelectric points
EP2601298B1 (en) 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
MX2013011366A (es) * 2011-03-30 2014-05-12 Chugai Pharmaceutical Co Ltd Retencion de las moleculas de union al antigeno en el plasma sanguineo y metodo para modificar la inmunogenicidad.
US9376495B2 (en) 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
WO2013002362A1 (ja) * 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP4074833A1 (en) * 2011-10-17 2022-10-19 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
IN2014CN03887A (enExample) 2011-10-27 2015-10-16 Genmab As
BR112014010257A2 (pt) 2011-10-31 2017-04-18 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
SMT201800092T1 (it) 2011-11-14 2018-03-08 Regeneron Pharma Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
AU2012340107B2 (en) 2011-11-18 2017-06-15 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
EP4624490A3 (en) 2012-02-09 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
MX2014010527A (es) 2012-03-02 2014-10-14 Regeneron Pharma Anticuerpos humanos para toxinas de clostridium difficile.
JP2015509380A (ja) 2012-03-06 2015-03-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 共通の軽鎖のマウス
EP3517548A1 (en) 2012-03-13 2019-07-31 NovImmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US9801362B2 (en) 2012-03-16 2017-10-31 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
HUE037659T2 (hu) 2012-03-16 2018-09-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
MX360368B (es) 2012-04-27 2018-10-29 Bioatla Llc Regiones de anticuerpo modificado y sus usos.
NZ703689A (en) 2012-06-12 2016-05-27 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US20150239991A1 (en) * 2012-09-25 2015-08-27 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
WO2014054804A1 (ja) 2012-10-05 2014-04-10 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
CA2889951C (en) 2012-11-02 2023-04-18 Zymeworks Inc. Crystal structures of heterodimeric fc domains
JP6506024B2 (ja) 2012-11-05 2019-04-24 全薬工業株式会社 抗体又は抗体組成物の製造方法
TWI864338B (zh) 2012-11-14 2024-12-01 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
MX387324B (es) 2013-01-10 2025-03-18 Genmab Bv Variantes de regiones fc de igg1 de humano y usos de las mismas.
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
RS57582B1 (sr) 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
KR20150126863A (ko) 2013-03-13 2015-11-13 리제너론 파마슈티칼스 인코포레이티드 공통 경쇄 마우스
HUE061977T2 (hu) 2013-03-13 2023-09-28 Regeneron Pharma Korlátozott immumglobulin könnyûlánc-repertoárt expresszáló egerek
BR112015021979A2 (pt) 2013-03-14 2017-08-29 Regeneron Pharma Anticorpos humanos para grem1
CA2906566C (en) 2013-03-14 2024-09-10 Macrogenics, Inc. Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor
JP6285532B2 (ja) * 2013-03-14 2018-02-28 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質ａに基づくクロマトグラフィを使用するタンパク質純度を増加させる方法
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
US11357866B2 (en) * 2013-04-03 2022-06-14 The Administrators Of The Tulane Educational Fund Expression of HIV inhibitors by mesenchymal stem cells
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
CA2904805A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP3041865A2 (en) * 2013-09-03 2016-07-13 NovImmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
CN104418947A (zh) * 2013-09-11 2015-03-18 香港大学 抗her2和抗-igf-ir的双特异性抗体及其用途
MY191512A (en) 2013-09-18 2022-06-28 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
CA2925256C (en) * 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
CA2931299C (en) 2013-11-20 2024-03-05 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
LT3074424T (lt) 2013-11-27 2025-05-26 Zymeworks Bc Inc. Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
JP2017029001A (ja) * 2013-12-19 2017-02-09 国立研究開発法人産業技術総合研究所 プロテインｇの細胞膜外ドメインの新規な改変型タンパク質
CN110903398B (zh) 2014-01-15 2023-08-15 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
CN110981957B (zh) 2014-01-15 2024-12-24 豪夫迈·罗氏有限公司 具有改善的蛋白A结合作用的Fc区变体
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
EP3107565A4 (en) * 2014-02-21 2017-08-23 Regeneron Pharmaceuticals, Inc. Methods, compositions and kits for cell specific modulation of target antigens
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
DK3805268T3 (da) 2014-02-28 2025-01-20 Merus Nv Antistof, der binder erbb-2 og erbb-3
TWI754319B (zh) * 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
SG10201808083VA (en) 2014-03-21 2018-10-30 Regeneron Pharma Vl antigen binding proteins exhibiting distinct binding characteristics
PL3122781T3 (pl) 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
KR20170017916A (ko) * 2014-05-13 2017-02-15 추가이 세이야쿠 가부시키가이샤 면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
DK3107938T3 (da) 2014-05-28 2022-07-11 Zymeworks Inc Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016054101A1 (en) 2014-09-29 2016-04-07 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
PT3215528T (pt) * 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
RU2713131C1 (ru) 2014-11-06 2020-02-03 Ф. Хоффманн-Ля Рош Аг ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP6696982B2 (ja) 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
HK1245171A1 (zh) 2014-11-26 2018-08-24 Xencor, Inc. 结合cd3和cd38的异二聚体抗体
ES2717308T3 (es) 2014-12-06 2019-06-20 Gemoab Monoclonals Gmbh Células madre pluri- o multi-potentes genéticamente modificadas y sus usos
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
EP3789039A1 (en) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
KR102618312B1 (ko) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
TWI735433B (zh) 2015-03-27 2021-08-11 美商再生元醫藥公司 偵測生物污染物之組成物及方法
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
EP3294775B1 (en) 2015-05-12 2021-07-14 Regeneron Pharmaceuticals, Inc. Multimeric protein purity determination
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
KR20250091329A (ko) 2015-06-15 2025-06-20 누맙 세러퓨틱스 아게 이종 이량체 다중 특이적 항체 포맷
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
AU2016284871B2 (en) 2015-06-23 2022-09-29 Innate Pharma Multispecific NK engager proteins
JP6993958B2 (ja) 2015-07-06 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性抗原結合分子およびその使用
EP3319996B1 (en) 2015-07-09 2024-01-03 Genmab A/S Bispecific and multispecific antibodies and method for isolation of such
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
CA2991805A1 (en) 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
AU2016312259B2 (en) 2015-08-26 2018-12-06 Bison Therapeutics Inc. Multispecific antibody platform and related methods
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
CN108283001B (zh) 2015-10-08 2022-08-19 酵活有限公司 包含κ和λ轻链的抗原结合多肽构建体及其用途
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
JP7296728B2 (ja) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
WO2017079768A1 (en) 2015-11-08 2017-05-11 Genentech, Inc. Methods of screening for multispecific antibodies
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
MX2018006333A (es) 2015-12-01 2018-08-01 Genmab Bv Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
ES2954153T3 (es) 2015-12-22 2023-11-20 Regeneron Pharma Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
SG11201803989WA (en) * 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
GB201602156D0 (en) * 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
EP3431102A4 (en) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
BR112018071283A2 (pt) * 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
US11530277B2 (en) 2016-04-20 2022-12-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
WO2017190079A1 (en) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
AU2017255077B2 (en) 2016-04-28 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455241B1 (en) 2016-05-11 2022-02-23 Cytiva BioProcess R&D AB Method of cleaning and/or sanitizing a separation matrix
JP7122974B2 (ja) 2016-05-11 2022-08-22 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 変異免疫グロブリン結合ポリペプチド
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
TWI822521B (zh) 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
SG10202102885UA (en) 2016-05-20 2021-05-28 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide rnas
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
RU2019102008A (ru) 2016-06-28 2020-07-28 Ксенкор, Инк. Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
MA45554A (fr) 2016-07-01 2019-05-08 Resolve Therapeutics Llc Fusions de binucléase optimisées.
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
WO2018039131A1 (en) 2016-08-22 2018-03-01 Protiva Biotherapeutics, Inc. Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR102520731B1 (ko) 2016-09-23 2023-04-14 리제너론 파아마슈티컬스, 인크. 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
EP3535291A1 (en) 2016-11-01 2019-09-11 Genmab B.V. Polypeptide variants and uses thereof
EP3535294B1 (en) 2016-11-07 2025-02-12 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
EP3541843A1 (en) 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
EP3559032A1 (en) 2016-12-23 2019-10-30 Innate Pharma Heterodimeric antigen binding proteins
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
TW201837174A (zh) 2017-02-07 2018-10-16 日商第一三共股份有限公司 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子
BR112019015900A2 (pt) 2017-02-10 2020-04-07 Genmab B.V. polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
CN110997714B (zh) 2017-02-17 2024-05-03 赛诺菲 对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
EP3589650A1 (en) 2017-03-02 2020-01-08 Novartis AG Engineered heterodimeric proteins
EP3601351A1 (en) 2017-03-27 2020-02-05 Celgene Corporation Methods and compositions for reduction of immunogenicity
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
CN119285787A (zh) 2017-03-31 2025-01-10 健玛保控股有限公司 双特异性抗cd37抗体、单克隆抗cd37抗体及其使用方法
JP7209298B2 (ja) 2017-03-31 2023-01-20 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc. anticorpos anti-cd137 e métodos de uso dos mesmos
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
EP3625264B9 (en) 2017-05-17 2023-10-25 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
KR20200014379A (ko) * 2017-06-05 2020-02-10 얀센 바이오테크 인코포레이티드 비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
US12098203B2 (en) 2017-06-05 2024-09-24 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
EP3635005A1 (en) 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
AU2018281280B2 (en) 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
CN118853581A (zh) 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
WO2019006034A1 (en) 2017-06-27 2019-01-03 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED ASGR1 LOCUS
SI3645551T1 (sl) 2017-06-27 2024-06-28 Regeneron Pharmaceuticals, Inc. S tropizmi spremenjeni rekombinantni virusni vektorji in njihova uporaba za tarčni vnos genetskega materiala v človeške celice
BR112019027729A2 (pt) 2017-06-27 2020-08-18 Neuracle Science Co., Ltd anticorpos anti-fam19a5 e seus usos
WO2019005756A1 (en) 2017-06-28 2019-01-03 The Rockefeller University CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE
IL299348B2 (en) 2017-06-28 2025-05-01 Regeneron Pharma Antigen-binding proteins against human papillomavirus and methods of using them
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
KR20210084695A (ko) 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
CN111566214B (zh) * 2017-07-06 2024-03-08 日东纺绩株式会社 抗人IgG4单克隆抗体及利用该抗体的人IgG4测定试剂
TWI865430B (zh) 2017-07-24 2024-12-11 美商再生元醫藥公司 穩定化之抗體組合物及其製法
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
JP7801095B2 (ja) * 2017-08-01 2026-01-16 エイビー セラピューティクス インコーポレイテッド 二重特異性抗体およびその使用
CN118126157A (zh) 2017-08-03 2024-06-04 美国安进公司 白介素-21突变蛋白和治疗方法
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CN111315767B (zh) 2017-08-22 2025-03-18 萨纳生物有限责任公司 可溶性干扰素受体及其用途
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
WO2019055841A1 (en) * 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
BR112020004977A2 (pt) 2017-09-29 2020-10-06 Regeneron Pharmaceuticals, Inc. moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos
KR102956517B1 (ko) 2017-10-04 2026-04-23 암젠 인크 트랜스타이레틴 면역글로불린 융합
WO2019077092A1 (en) 2017-10-20 2019-04-25 F. Hoffmann-La Roche Ag METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
IL274071B2 (en) 2017-10-30 2025-10-01 Hoffmann La Roche Method for generating in vivo multispecific antibodies from monospecific antibodies
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
KR20260090008A (ko) 2017-11-01 2026-06-16 추가이 세이야쿠 가부시키가이샤 생물 활성이 저하된 항체 배리언트 및 아이소폼
AU2018358804A1 (en) * 2017-11-02 2020-04-09 Bayer Aktiengesellschaft Bispecific antibodies binding ALK-1 and BMPR-2
CN117756946A (zh) * 2017-11-03 2024-03-26 莱蒂恩技术公司 用于用抗ror1免疫治疗来治疗癌症的组合物和方法
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3713959A1 (en) 2017-11-21 2020-09-30 Innate Pharma Multispecific antigen binding proteins
JP7361031B2 (ja) 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
CN111448217A (zh) 2017-12-22 2020-07-24 阿根思公司 双特异性抗原结合构建体
US20190194298A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
US12649798B2 (en) 2018-01-24 2026-06-09 Genmab B.V. Polypeptide variants and uses thereof
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
CA3085177A1 (en) 2018-01-31 2019-08-08 Regeneron Pharamaceuticals, Inc. System and method for characterizing size and charge variant drug product impurities
TW202411650A (zh) 2018-02-01 2024-03-16 美商再生元醫藥公司 治療性單株抗體之品質屬性的定量及模型化
JP7539834B2 (ja) 2018-02-01 2024-08-26 メモリアル スローン ケタリング キャンサー センター ガレクチン－３に対する抗体及びその使用方法
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
CR20200391A (es) 2018-02-08 2020-10-19 Genentech Inc Moléculas biespecíficas de unión al antígeno y métodos de uso
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
AU2019227531B2 (en) 2018-02-28 2025-01-30 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
IL276921B2 (en) 2018-03-01 2025-12-01 Regeneron Pharma Methods for altering body composition
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3765516A2 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US11054389B2 (en) 2018-03-19 2021-07-06 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
EP4534560A3 (en) 2018-03-24 2025-06-11 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
KR20210003814A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
JP7328990B2 (ja) 2018-04-30 2023-08-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
KR20240056644A (ko) 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
SG11202011461TA (en) 2018-06-01 2020-12-30 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
EA202190056A1 (ru) 2018-06-19 2021-05-28 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
TW202504917A (zh) 2018-06-21 2025-02-01 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
JP7513530B2 (ja) 2018-06-22 2024-07-09 ジェンマブ ホールディング ビー．ブイ． 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法
US12247065B2 (en) 2018-06-22 2025-03-11 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
CN112424358B (zh) 2018-06-26 2025-07-01 协和麒麟株式会社 与细胞粘附分子3结合的抗体
CA3104997A1 (en) 2018-06-26 2020-01-02 Kyowa Kirin Co., Ltd. Antibody binding to chondroitin sulfate proteoglycan 5
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
MX2021000239A (es) * 2018-07-10 2021-03-25 Regeneron Pharma Modificacion de moleculas de union para minimizar interacciones preexistentes.
EP3820900A1 (en) 2018-07-13 2021-05-19 Genmab A/S Variants of cd38 antibody and uses thereof
TWI902667B (zh) 2018-07-13 2025-11-01 美商再生元醫藥公司 醣基化肽之偵測及定量
MA53123A (fr) 2018-07-13 2021-05-19 Genmab As Thérapie à médiation par trogocytose utilisant des anticorps cd38
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
US20200064353A1 (en) 2018-08-13 2020-02-27 Regeneron Pharmaceuticals, Inc. Therapeutic Protein Selection in Simulated In Vivo Conditions
SG11202101369XA (en) 2018-08-17 2021-03-30 Regeneron Pharma Method and chromatography system for determining amount and purity of a multimeric protein
JP2021534408A (ja) 2018-08-17 2021-12-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｅ ｎｏｖｏタンパク質シークエンシングのための方法
MX2021002165A (es) 2018-08-23 2021-07-16 Regeneron Pharma Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos.
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
WO2020047067A1 (en) 2018-08-30 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
JP2022504287A (ja) 2018-10-03 2022-01-13 スターテン・バイオテクノロジー・ベー・フェー ヒト及びカニクイザルａｐｏｃ３に特異的な抗体、並びにその使用の方法
KR102884523B1 (ko) 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
AU2019354105A1 (en) 2018-10-04 2021-04-29 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-CD37 antibodies
US12590169B2 (en) 2018-10-11 2026-03-31 Inhibrx Biosciences, Inc. 5T4 single domain antibodies and therapeutic compositions thereof
AU2019356573B2 (en) 2018-10-11 2025-12-18 Inhibrx Biosciences, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
CN113166261A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
CA3115102A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Anti-npr1 antibodies and uses thereof
WO2020086893A1 (en) 2018-10-25 2020-04-30 Regeneron Pharmaceuticals, Inc. Methods for analysis of viral capsid protein composition
WO2020087065A1 (en) * 2018-10-26 2020-04-30 Teneobio, Inc. Heavy chain antibodies binding to cd38
CA3116717A1 (en) 2018-10-31 2020-05-07 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying a protein
CN113454111A (zh) 2018-11-06 2021-09-28 健玛保 抗体配制剂
JP7463366B2 (ja) 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
CA3110377A1 (en) 2018-11-21 2020-05-28 Regeneron Pharmaceuticals, Inc. Anti-staphylococcus antibodies and uses thereof
US11249089B2 (en) 2018-12-12 2022-02-15 Regeneron Pharmaceuticals, Inc. System and method of analysis of a protein using liquid chromatography-mass spectrometry
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
US11782023B2 (en) * 2018-12-19 2023-10-10 Regeneron Pharmaceuticals, Inc. Ce-western applications for antibody development
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
WO2020132024A1 (en) * 2018-12-19 2020-06-25 Regeneron Pharmaceuticals, Inc. Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
TWI772724B (zh) 2018-12-21 2022-08-01 英商克馬伯有限公司 具有共同輕鏈的FIXaxFX雙專一性抗體
JP7734075B2 (ja) 2018-12-24 2025-09-04 サノフイ 疑似ｆａｂベースの多重特異性結合タンパク質
CN113544145B (zh) * 2018-12-24 2024-12-17 首尔大学校产学协力团 中和1型干扰素的fc融合蛋白及其用途
MX2021004504A (es) 2019-01-02 2021-10-01 Neuracle Science Co Ltd Anti-familia con similitud de secuencia 19, anticuerpos del miembro a5 y método de uso de los mismos.
JP2022517720A (ja) 2019-01-16 2022-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ジスルフィド結合を特徴付けるための方法
CN113660956B (zh) 2019-01-28 2024-10-29 Ab诊疗公司 双特异性抗体及其用途
CA3126712A1 (en) 2019-01-31 2020-08-06 Regeneron Pharmaceuticals, Inc. Native microfluidic ce-ms analysis of antibody charge heterogeneity
JP2022519631A (ja) 2019-02-12 2022-03-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
SG11202109122SA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Anti-tcr antibody molecules and uses thereof
WO2020172598A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CN119735688A (zh) 2019-02-26 2025-04-01 茵思博纳公司 高-亲和力抗-mertk抗体及其用途
EP3930850A1 (en) 2019-03-01 2022-01-05 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
EP3945800A1 (en) 2019-04-03 2022-02-09 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
JP7506686B2 (ja) 2019-04-04 2024-06-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化凝固因子１２遺伝子座を含む非ヒト動物
MX2021012335A (es) 2019-04-10 2021-11-12 Regeneron Pharma Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
US20220315661A1 (en) 2019-05-09 2022-10-06 Genmab B.V. Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
US20200393455A1 (en) 2019-05-21 2020-12-17 Regeneron Pharmaceuticals, Inc. Methods for identifying and quantitating host cell protein
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
PT3979790T (pt) 2019-06-05 2026-05-05 Regeneron Pharma Roedores possuindo um reportrio limitado de cadeias leves lambda expressadas a partir do lcus kappa e suas utilizaes
CN113966343A (zh) 2019-06-11 2022-01-21 瑞泽恩制药公司 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法
AU2020293237A1 (en) 2019-06-13 2022-01-06 Regeneron Pharmaceuticals, Inc. Methods for removing undesired components during multistage chromatographic processes
JP7743314B2 (ja) 2019-06-21 2025-09-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用
EP3986933A1 (en) 2019-06-21 2022-04-27 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
US20220324924A1 (en) 2019-07-08 2022-10-13 Amgen Inc. Multispecific transthyretin immunoglobulin fusions
JP7359864B2 (ja) 2019-07-10 2023-10-11 中外製薬株式会社 クローディン６結合分子およびその使用
GB201910900D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
CN114585651A (zh) 2019-08-08 2022-06-03 再生元制药公司 新型抗原结合分子形式
MX2022001942A (es) 2019-08-15 2022-07-27 Regeneron Pharma Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.
TW202120537A (zh) 2019-08-15 2021-06-01 美商健生生物科技公司 用於經改善的單鏈可變片段之材料及方法
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
JP7611908B2 (ja) 2019-10-28 2025-01-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗血球凝集素抗体およびその使用方法
AU2020379735A1 (en) 2019-11-05 2022-05-26 Regeneron Pharmaceuticals, Inc. N-terminal SCFV multispecific binding molecules
JP7880817B2 (ja) 2019-11-06 2026-06-26 ジェンマブ ビー．ブイ． 抗体変種の組み合わせおよびその使用
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
US11730793B2 (en) 2019-11-25 2023-08-22 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
JP7693672B2 (ja) 2019-12-06 2025-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法
IL309560B2 (en) 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
WO2021116337A1 (en) 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
EP4141025A4 (en) 2019-12-26 2024-04-24 ABL Bio, Inc. Method for purifying biologically active peptide by using protein a affinity chromatography
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN115280151A (zh) 2020-01-08 2022-11-01 瑞泽恩制药公司 使用氨基酸增强质谱分析中的信号
MX2022008050A (es) 2020-01-16 2022-07-27 Genmab As Formulaciones de anticuerpos anti cumulo de diferenciacion 38 (cd38) y usos de las mismas.
CA3165060C (en) 2020-01-21 2023-06-20 Yiming Zhao Deglycosylation methods for electrophoresis of glycosylated proteins
MX2022009229A (es) 2020-01-27 2022-08-16 Regeneron Pharma Cuantificacion en formato multiple por etiquetas de masa en tandem de modificaciones postraduccionales de proteinas.
WO2021154791A1 (en) 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
EP4097129A1 (en) 2020-01-29 2022-12-07 Inhibrx, Inc. Cd28 single domain antibodies and multivalent and multispecific constructs thereof
US11598756B2 (en) 2020-01-30 2023-03-07 Regeneron Pharmaceuticals, Inc. Platform for native liquid chromatography-mass spectrometry
IL294907A (en) 2020-01-31 2022-09-01 Regeneron Pharma High confidence compound identification by liquid chromatography-mass spectrometry
EP4099821A1 (en) 2020-02-07 2022-12-14 Regeneron Pharmaceuticals, Inc. <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use
US11945872B2 (en) 2020-02-11 2024-04-02 Regeneron Pharmaceuticals, Inc. Anti-ACVR1 antibodies and uses thereof
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
US20230102342A1 (en) 2020-03-23 2023-03-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
JP7664943B2 (ja) 2020-03-25 2025-04-18 イーライ リリー アンド カンパニー 多重特異性結合タンパク質およびそれを開発する方法
CA3175577A1 (en) 2020-03-30 2021-10-07 Mie University Bispecific antibody
JP2023522624A (ja) 2020-04-14 2023-05-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 直交部分最小二乗によるクロマトグラフィ性能の紫外線モニタリング
AU2021261420A1 (en) 2020-04-24 2022-12-01 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
WO2021228904A1 (en) 2020-05-11 2021-11-18 Academisch Medisch Centrum Neutralizing antibodies binding to the spike protein of sars-cov-2 suitable for use in the treatment of covid-19, compositions comprising the same and uses thereof
MX2022014090A (es) 2020-05-12 2023-02-27 Regeneron Pharma Anticuerpos antagonistas anti-glp1r y metodos de uso de los mismos.
KR20230009430A (ko) 2020-05-12 2023-01-17 리제너론 파아마슈티컬스, 인크. 신규 il10 효능제 및 그의 사용 방법
EP4149632A1 (en) 2020-05-14 2023-03-22 Xencor, Inc. Heterodimeric antibodies that bind msln and cd3
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
EP4171215A2 (en) 2020-06-26 2023-05-03 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ace2 locus
US20230293680A1 (en) 2020-07-23 2023-09-21 Genmab B.V. A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
AU2021328375A1 (en) 2020-08-18 2023-04-13 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
CN116249713A (zh) 2020-08-20 2023-06-09 瑞泽恩制药公司 利用激活素a拮抗剂预防和治疗心功能不全和covid-19的方法
JP2023539645A (ja) 2020-08-26 2023-09-15 マレンゴ・セラピューティクス，インコーポレーテッド Ｎｋｐ３０に結合する抗体分子およびその使用
CA3190573A1 (en) 2020-08-26 2022-03-03 Andreas Loew Methods of detecting trbc1 or trbc2
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
KR20230058094A (ko) 2020-08-31 2023-05-02 리제너론 파아마슈티컬스, 인크. 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
JP7905328B2 (ja) 2020-09-18 2026-08-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用
PH12023550779A1 (en) 2020-09-28 2023-11-20 Angitia Biomedicines Ltd Anti-sclerostin constructs and uses thereof
US20230365714A1 (en) 2020-10-02 2023-11-16 Genmab A/S Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
WO2022082030A2 (en) 2020-10-15 2022-04-21 Gritstone Bio, Inc. Antigen-binding proteins and related methods of use
CA3198049A1 (en) 2020-10-15 2022-04-21 UCB Biopharma SRL Binding molecules that multimerise cd45
US11866502B2 (en) 2020-10-22 2024-01-09 Regeneron Pharmaceuticals, Inc. Anti-FGFR2 antibodies and methods of use thereof
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
EP4240493A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
CN117120477A (zh) 2020-11-10 2023-11-24 上海齐鲁制药研究中心有限公司 针对密蛋白18a2和cd3的双特异性抗体及其应用
EP4251128A1 (en) 2020-11-25 2023-10-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
CN114539416B (zh) * 2020-11-26 2024-11-08 盛禾(中国)生物制药有限公司 一种双特异性抗体的层析纯化工艺
IL303675A (en) 2020-12-17 2023-08-01 Regeneron Pharma Production of protein thermal microgels
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists
CA3202429A1 (en) 2020-12-20 2022-06-23 Regeneron Pharmaceuticals, Inc. Methods for identification of scrambled disulfides in biomolecules
US20250223379A1 (en) * 2021-01-11 2025-07-10 Adimab, Llc Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof
WO2022155503A1 (en) 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
PY2204506A (es) 2021-01-28 2022-08-30 Talem Therapeutics Llc Anticuerpos antiglicoproteína de espiga y su uso terapéutico
CA3206253A1 (en) 2021-02-04 2022-08-11 Heung Rok Park Anti-pd-1 antibody and use thereof
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
TW202246325A (zh) 2021-03-03 2022-12-01 美商再生元醫藥公司 用於定量及修飾蛋白質黏度之系統及方法
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
TW202304991A (zh) 2021-03-29 2023-02-01 日商第一三共股份有限公司 穩定的多重特異性分子及其利用
AR125255A1 (es) 2021-04-02 2023-06-28 Regeneron Pharma Métodos de predicción y modulación de la glicación de una proteína
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
MX2023012724A (es) 2021-04-27 2024-02-08 Amgen Inc Modulación de la calidad de producto de anticuerpos multiespecíficos asimétricos a través del uso de la temperatura.
BR112023022878A2 (pt) * 2021-05-04 2024-01-23 Regeneron Pharma Agonistas do receptor fgf21 multiespecíficos e seus usos
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
AU2022281461A1 (en) 2021-05-25 2024-01-04 Edelweiss Immune Inc C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
KR20240019786A (ko) 2021-06-09 2024-02-14 이나뜨 파르마 에스.에이. Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
TW202322850A (zh) * 2021-08-05 2023-06-16 美商美國禮來大藥廠 抗體最佳化
CA3229369A1 (en) 2021-08-16 2023-02-23 Regeneron Pharmaceuticals, Inc. Novel il27 receptor agonists and methods of use thereof
US20240360233A1 (en) 2021-08-27 2024-10-31 Board Of Regents, The University Of Texas System Anti-tslpr (crlf2) antibodies
AR127743A1 (es) 2021-09-06 2024-02-28 Genmab Bv Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
US20250017183A1 (en) 2021-11-04 2025-01-16 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified cacng1 locus
US12559576B2 (en) 2021-11-11 2026-02-24 Regeneron Pharmaceuticals, Inc. CD20-PD1 binding molecules and methods of use thereof
MX2024006187A (es) 2021-11-24 2024-08-14 Regeneron Pharma Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4.
WO2023100829A1 (ja) 2021-11-30 2023-06-08 第一三共株式会社 プロテアーゼ分解性マスク抗体
WO2023107957A1 (en) 2021-12-06 2023-06-15 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof
AU2022408167A1 (en) 2021-12-08 2024-06-06 Regeneron Pharmaceuticals, Inc. Mutant myocilin disease model and uses thereof
EP4451863A1 (en) 2021-12-20 2024-10-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising humanized ace2 and tmprss loci
MX2024008055A (es) 2022-01-07 2024-09-06 Regeneron Pharma Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1.
TW202337900A (zh) 2022-01-12 2023-10-01 美商再生元醫藥公司 改良使用親和層析的異二聚蛋白質自雜質之解析的方法
US20250084169A1 (en) 2022-01-12 2025-03-13 Biomolecular Holdings Llc Nk/monocyte engagers
WO2023150798A1 (en) 2022-02-07 2023-08-10 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
AU2023218678A1 (en) 2022-02-09 2024-08-01 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
CN118613498A (zh) 2022-02-11 2024-09-06 瑞泽恩制药公司 用于筛选4R Tau靶向剂的组合物和方法
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
IL314993A (en) * 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
US20230340128A1 (en) 2022-02-24 2023-10-26 Xencor, Inc. Anti-cd28 x anti-msln antibodies
EP4482865A1 (en) 2022-02-24 2025-01-01 Xencor, Inc. Anti-cd28 x anti-trop2 antibodies
TW202400228A (zh) 2022-02-25 2024-01-01 美商再生元醫藥公司 減輕細胞激素釋放症候群的給藥方案
WO2023176881A1 (ja) 2022-03-16 2023-09-21 第一三共株式会社 多重特異的分子と免疫チェックポイント阻害剤の組み合わせ
IL315405A (en) 2022-03-17 2024-11-01 Regeneron Pharma Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2023212677A2 (en) 2022-04-29 2023-11-02 Regeneron Pharmaceuticals, Inc. Identification of tissue-specific extragenic safe harbors for gene therapy approaches
AU2023269134A1 (en) 2022-05-09 2024-12-12 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
IL316892A (en) 2022-05-11 2025-01-01 Regeneron Pharma Multispecific proprotein binding molecules and their uses
CA3253038A1 (en) 2022-05-12 2023-11-16 Genmab A/S LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY
TW202409090A (zh) 2022-05-12 2024-03-01 丹麥商珍美寶股份有限公司 在組合療法中能夠結合到ｃｄ２７之結合劑
WO2023224912A1 (en) 2022-05-16 2023-11-23 Regeneron Pharmaceuticals, Inc. Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
CA3252182A1 (en) 2022-05-18 2023-11-23 Regeneron Pharmaceuticals, Inc. MULTISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND TO CD38 AND 4-1BB AND ASSOCIATED USES
JP2025519158A (ja) 2022-05-27 2025-06-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド インターロイキン－２プロタンパク質及びその使用
CN119654338A (zh) 2022-06-04 2025-03-18 再生元制药公司 白细胞介素-2蛋白质原及其用途
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2024020199A1 (en) 2022-07-21 2024-01-25 Regeneron Pharmaceuticals, Inc. Native microfluidic ce-ms analysis of antibody charge heterogeneity
IL318627A (en) 2022-07-29 2025-03-01 Regeneron Pharma Anti-TFR charge fusions and methods of using them
CN120112164A (zh) 2022-07-29 2025-06-06 瑞泽恩制药公司 包含修饰的转铁蛋白受体基因座的非人动物
CN120659627A (zh) 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
US20240043560A1 (en) 2022-08-02 2024-02-08 Regeneron Pharmaceuticals, Inc. Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 Antibodies
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
KR20250048583A (ko) 2022-08-18 2025-04-09 리제너론 파아마슈티컬스, 인크. 인터페론 전구단백질 및 이의 용도
EP4587122A1 (en) 2022-09-15 2025-07-23 Avidicure IP B.V. Multispecific antigen binding proteins for stimulating nk cells and use thereof
EP4593590A1 (en) 2022-09-29 2025-08-06 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
IL319818A (en) 2022-10-10 2025-05-01 Regeneron Pharma Methods for reducing alloantibody levels in patients requiring solid organ transplantation
AU2023364731A1 (en) 2022-10-21 2025-04-03 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
US12030945B2 (en) 2022-10-25 2024-07-09 Seismic Therapeutic, Inc. Variant IgG Fc polypeptides and uses thereof
WO2024092133A1 (en) 2022-10-27 2024-05-02 Regeneron Pharmaceuticals, Inc. Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification
US20250382378A1 (en) 2022-10-31 2025-12-18 Genmab A/S Cd38 antibodies and uses thereof
AU2023371614A1 (en) 2022-11-04 2025-05-15 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
AU2023379457A1 (en) 2022-11-14 2025-05-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
CN120456916A (zh) 2022-11-14 2025-08-08 瑞泽恩制药公司 抗fgfr3抗体和抗原结合片段及其使用方法
WO2024123698A1 (en) 2022-12-08 2024-06-13 Regeneron Pharmaceuticals, Inc. Methods to characterizing a fragment crystallizable domain of a bispecific antibody
JP2026500017A (ja) 2022-12-16 2026-01-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａａｖ粒子に結合する抗原結合分子及びその使用
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
EP4638729A1 (en) 2022-12-23 2025-10-29 Regeneron Pharmaceuticals, Inc. Ace2 fusion proteins and uses thereof
CN121002062A (zh) 2023-01-13 2025-11-21 再生元制药公司 Fgfr3结合分子及其使用方法
AU2024207005A1 (en) 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
CN121002059A (zh) 2023-01-20 2025-11-21 因外泰克斯公司 用于伴侣动物的双特异性结合剂
WO2024173248A1 (en) 2023-02-13 2024-08-22 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
IL322890A (en) 2023-02-28 2025-10-01 Regeneron Pharma Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
CN121057744A (zh) 2023-02-28 2025-12-02 再生元制药公司 多价抗刺突蛋白结合分子及其用途
US20250043001A1 (en) 2023-03-14 2025-02-06 Xencor, Inc. Anti-cd28 compositions
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
AU2024238898A1 (en) 2023-03-22 2025-10-16 Salubris Biotherapeutics, Inc. Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof
CN121057752A (zh) 2023-04-07 2025-12-02 达科纳治疗有限公司 铰链经修饰的双特异性抗体
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
AU2024255999A1 (en) 2023-04-14 2025-10-16 Xencor, Inc. Anti-cd28 x anti-trop2 antibodies
IL323870A (en) 2023-04-14 2025-12-01 Xencor Inc Antibodies against x cd28 and anti enpp3
JP2026514305A (ja) 2023-05-01 2026-05-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド フェノールまたはベンジルアルコールを使用した複数回投与抗体医薬品
CN121039163A (zh) 2023-05-02 2025-11-28 瑞泽恩制药公司 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
WO2024233926A1 (en) 2023-05-10 2024-11-14 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
KR20260026098A (ko) 2023-05-12 2026-02-25 리제너론 파아마슈티컬스, 인크. 인터페론 수용체 길항제 및 이의 용도
IL324457A (en) 2023-05-12 2026-01-01 Genmab As Antibodies capable of binding to ox40, their variants and uses thereof
WO2024243048A1 (en) 2023-05-19 2024-11-28 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to il12 receptor
IL324966A (en) 2023-06-08 2026-01-01 Regeneron Pharma An animal model with rapid onset of Alzheimer's beta-amyloid plaque pathology
WO2024251884A1 (en) 2023-06-09 2024-12-12 Innate Pharma Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
CN121646605A (zh) 2023-06-11 2026-03-10 再生元制药公司 环化抗体分子
CN121399157A (zh) 2023-06-12 2026-01-23 美国安进公司 淋巴毒素β受体激动剂结合蛋白
EP4727973A1 (en) 2023-06-16 2026-04-22 Regeneron Pharmaceuticals, Inc. Cd40 x cd40 bispecific antigen-binding molecules and uses thereof
CN121729432A (zh) 2023-06-23 2026-03-24 派克西斯肿瘤学公司 抗klrg1抗体及其用途
IL325400A (en) 2023-07-10 2026-02-01 Regeneron Pharma Anti-human CACNG1 antibody-drug conjugates and their uses
JP2026524012A (ja) 2023-07-10 2026-07-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性ｐｄ－ｌ１×４－１ｂｂ抗体およびそれらの使用方法
JP2026524011A (ja) 2023-07-10 2026-07-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性ｐｄ－ｌ１×ｃｄ２８抗体およびそれらの使用方法
KR20260042526A (ko) 2023-07-19 2026-03-31 리제너론 파아마슈티컬스, 인크. 항-인자 XII/XIIa 항체 및 이의 용도
IL326018A (en) 2023-07-28 2026-03-01 Regeneron Pharma Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease
AR133384A1 (es) 2023-07-28 2025-09-24 Regeneron Pharma Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida
WO2025030044A1 (en) 2023-08-02 2025-02-06 Regeneron Pharmaceuticals, Inc. Methods of treating clear cell renal cell carcinoma with bispecific anti-psma x anti-cd28 antibodies
KR20260046131A (ko) 2023-08-02 2026-04-06 리제너론 파아마슈티컬스, 인크. 이중특이적 항-PSMA x 항-CD28 항체를 이용한 전이성 거세-저항성 전립선암의 치료 방법
US20250188166A1 (en) 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
EP4771050A1 (en) 2023-08-28 2026-07-08 Regeneron Pharmaceuticals, Inc. Anti-cxcr4 antibodies and uses thereof
KR20260081298A (ko) 2023-08-28 2026-06-02 젠코어 인코포레이티드 항-cd20 x 항-cd28 조합 요법
IL327756A (en) 2023-10-23 2026-06-01 Diagonal Therapeutics Inc Heteromeric agonistic antibodies to il-18 receptor
WO2025090973A2 (en) 2023-10-27 2025-05-01 Xencor, Inc. Anti-trop2 x anti-pdl1 x anti-cd28 antibodies
KR20260113057A (ko) 2023-11-14 2026-07-21 리제너론 파아마슈티컬스, 인크. 조작된 중쇄 가변 도메인 및 이의 용도
WO2025111473A1 (en) 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus
TW202539732A (zh) 2023-11-29 2025-10-16 美商再生元醫藥公司 以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法
CN122249464A (zh) 2023-11-30 2026-06-19 金麦安博股份有限公司 在组合疗法中的能够结合ox40的抗体
WO2025122614A1 (en) 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Il18 receptor agonists and methods of use thereof
GB202318820D0 (en) 2023-12-08 2024-01-24 UCB Biopharma SRL Antibodies
TW202542187A (zh) 2023-12-12 2025-11-01 美商再生元醫藥公司 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法
AU2024400671A1 (en) 2023-12-15 2026-07-16 Kyowa Kirin Co., Ltd. Divalent bet decomposition agent and targeting molecule-drug complex
AU2024403128A1 (en) 2023-12-19 2026-06-25 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025151806A1 (en) 2024-01-11 2025-07-17 Regeneron Pharmaceuticals, Inc. P75 neurotrophin receptor (p75ntr)-binding proteins and p75ntr-mediated delivery to the nervous system
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025171124A1 (en) 2024-02-07 2025-08-14 Regeneron Pharmaceuticals, Inc. Methods of treating prostate cancer with bispecific anti-psma x anti-cd3 antibodies and bispecific anti-psma x anti-cd28 antibodies
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191139A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025199278A2 (en) 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Masked multispecific antigen-binding molecules with cleavable linkers
WO2025199243A1 (en) 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Trivalent multispecific binding molecules and methods of use thereof
WO2025213061A2 (en) 2024-04-04 2025-10-09 Ethyreal Bio, Inc. Anti-tshr antibodies and uses thereof
WO2025221728A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof
TW202611075A (zh) 2024-05-13 2026-03-16 美商再生元醫藥公司 以雙特異性BCMAxCD3抗體治療輕鏈類澱粉變性症之方法
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025244973A1 (en) 2024-05-20 2025-11-27 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies
US20250361309A1 (en) 2024-05-24 2025-11-27 Regeneron Pharmaceuticals, Inc. Tumor-targeted split il12 receptor agonists
WO2025250495A1 (en) 2024-05-28 2025-12-04 Regeneron Pharmaceuticals, Inc. Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals
WO2025255452A2 (en) 2024-06-07 2025-12-11 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind to aav particles and uses thereof
WO2025255480A1 (en) 2024-06-07 2025-12-11 Regeneron Pharmaceuticals, Inc. Tetravalent multispecific binding molecules and methods of use thereof
US20260055171A1 (en) 2024-06-11 2026-02-26 Regeneron Pharmaceuticals, Inc. Vegf antagonists and methods of use thereof
US20260000758A1 (en) 2024-06-28 2026-01-01 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
TW202617776A (zh) 2024-07-10 2026-05-01 美商再生元醫藥公司 治療ｓｍａｒｃｂ１缺陷型癌症之方法
US20260014252A1 (en) 2024-07-11 2026-01-15 Regeneron Pharmaceuticals, Inc. GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof
WO2026025058A1 (en) 2024-07-25 2026-01-29 Regeneron Pharmaceuticals, Inc. Aav viral particles retargeted to egfr-expressing cancer cells
WO2026039325A2 (en) 2024-08-12 2026-02-19 Regeneron Pharmaceuticals, Inc. Modified mtm1 genes and uses thereof
WO2026039791A1 (en) 2024-08-16 2026-02-19 Regeneron Pharmaceuticals, Inc. Tumor-targeted split il2 receptor agonists
WO2026044000A1 (en) 2024-08-20 2026-02-26 Ethyreal Bio, Inc. Multispecific antibodies and methods of use thereof
WO2026050255A2 (en) 2024-08-27 2026-03-05 Regeneron Pharmaceuticals, Inc. Anti-slc3a2-apis antigen-binding proteins and methods of use thereof
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2026055669A2 (en) 2024-09-09 2026-03-12 Xencor, Inc. Anti-tl1a x anti-il23 antibodies
WO2026059917A1 (en) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with proteasome inhibitors
WO2026059920A1 (en) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with pd1/pd-l1 inhibitors
US20260070998A1 (en) 2024-09-10 2026-03-12 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with cd38 inhibitors
WO2026059923A1 (en) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with an immunomodulator
US20260158137A1 (en) 2024-09-10 2026-06-11 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors
WO2026075989A1 (en) 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Engineered igg molecules and methods of use thereof
WO2026076013A1 (en) 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Tumor-targeted il2 receptor agonists and multispecific t-cell engagers
WO2026075981A1 (en) 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Methods of analyzing heterodimeric proteins
US20260234273A1 (en) 2024-10-09 2026-08-13 Diagonal Therapeutics Inc. Bone morphogenetic protein receptor type 2 (bmprii) antibodies
WO2026080752A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. De novo antibodies to activin a receptor like type 1 (alk1)
WO2026080757A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. Activin receptor type ii a/b (actriia/b) antibodies
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
US20260113004A1 (en) 2024-10-21 2026-04-23 Rgb Systems, Inc. Class d amplifier with current mode control
US20260109746A1 (en) 2024-10-22 2026-04-23 Gilead Sciences, Inc. Cd4-targeted il-15 molecules and methods of use
WO2026087747A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof
WO2026087748A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof
US20260146100A1 (en) 2024-10-30 2026-05-28 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules that bind cd22 and 4-1bb and methods of use thereof
WO2026096576A1 (en) 2024-10-30 2026-05-07 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules that bind psma and 4-1bb and methods of use thereof
WO2026093563A2 (en) 2024-10-31 2026-05-07 Molecular Partners Ag Multispecific binding proteins and their use
WO2026102148A1 (en) 2024-11-07 2026-05-15 Diagonal Therapeutics Inc. Alk1 / bmprii bispecific antibodies for treatment of ocular diseases
WO2026102284A1 (en) 2024-11-08 2026-05-15 Regeneron Pharmaceuticals, Inc. Humanized stathmin2 allele to track human tdp-43-dependent splicing changes caused by tdp-43 pathology
WO2026112457A2 (en) 2024-11-21 2026-05-28 Regeneron Pharmaceuticals, Inc. Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof
WO2026136279A1 (en) 2024-12-16 2026-06-25 Regeneron Pharmaceuticals, Inc. Engineered single domain antibody constructs and methods of use thereof
WO2026139739A1 (en) 2024-12-27 2026-07-02 Bright Peak Therapeutics Ag Dual binding compositions targeting vegfa and pd-1
WO2026161391A2 (en) 2025-01-21 2026-07-30 Bristol-Myers Squibb Company Cd19 binding molecules including cd3- and cd19- bispecific t cell engagers and related methods and uses
WO2026161387A1 (en) 2025-01-21 2026-07-30 Bristol-Myers Squibb Company Cd3 binding molecules and related methods and uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002781A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444878A (en) * 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
WO1986002068A1 (fr) 1984-09-26 1986-04-10 Takeda Chemical Industries, Ltd. Separation mutuelle de proteines
JPH09100296A (ja) * 1984-09-26 1997-04-15 Takeda Chem Ind Ltd 蛋白質の相互分離方法
GB8626413D0 (en) 1986-11-05 1986-12-03 Gilliland L K Antibodies
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
AU4116793A (en) * 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5945311A (en) * 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
DE4419399C1 (de) * 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JPH0987300A (ja) * 1995-07-14 1997-03-31 Takeda Chem Ind Ltd 雑種蛋白質およびその用途
DK0826695T3 (da) 1996-09-03 2002-04-15 Gsf Forschungszentrum Umwelt Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer
EP0826696B1 (de) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
ATE255420T1 (de) 1998-09-25 2003-12-15 Horst Lindhofer Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
US7169903B2 (en) 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US20030224000A1 (en) * 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
SI1545574T1 (sl) * 2002-09-13 2014-10-30 Biogen Idec Inc. Postopek za čiščenje polipeptidov s simulirano "moving bed" kromatografijo
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2005021594A2 (en) * 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
NZ569988A (en) * 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
JP5144499B2 (ja) * 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
CA2669412A1 (en) * 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
WO2008152537A2 (en) * 2007-06-14 2008-12-18 Zenotech Laboratories Limited Humanized monoclonal antibodies against human epidermal growth factor receptor, use and method thereof
US9266967B2 (en) * 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002781A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins

Also Published As

Publication number Publication date
SI2975051T1 (sl) 2021-08-31
MX384993B (es) 2025-03-14
IL217000A0 (en) 2012-02-29
KR20180034638A (ko) 2018-04-04
US11168111B2 (en) 2021-11-09
MY192182A (en) 2022-08-04
EP3916011A1 (en) 2021-12-01
RU2012102602A (ru) 2013-08-10
MY152963A (en) 2014-12-15
US20260209266A1 (en) 2026-07-23
JP5816170B2 (ja) 2015-11-18
MX368932B (es) 2019-10-22
US9982013B2 (en) 2018-05-29
CA2766220C (en) 2021-02-09
AU2015207952A1 (en) 2015-08-20
JP2015227386A (ja) 2015-12-17
SG176868A1 (en) 2012-02-28
ES2865648T3 (es) 2021-10-15
CY1124358T1 (el) 2022-07-22
IL265732A (en) 2019-05-30
US9309326B2 (en) 2016-04-12
US20160251395A1 (en) 2016-09-01
JP2012531439A (ja) 2012-12-10
CN102471378A (zh) 2012-05-23
US20140248664A1 (en) 2014-09-04
KR20160141879A (ko) 2016-12-09
TWI507525B (zh) 2015-11-11
EP2975051B1 (en) 2021-04-14
IL265732B (en) 2020-03-31
AU2010265933A1 (en) 2012-01-19
PT2975051T (pt) 2021-05-04
US8586713B2 (en) 2013-11-19
KR102010827B1 (ko) 2019-08-14
KR20140112569A (ko) 2014-09-23
HK1219283A1 (en) 2017-04-28
JP2022173489A (ja) 2022-11-18
US20100331527A1 (en) 2010-12-30
RU2647758C2 (ru) 2018-03-19
KR20120027055A (ko) 2012-03-20
LT2975051T (lt) 2021-07-12
HUE054257T2 (hu) 2021-08-30
JP2021004261A (ja) 2021-01-14
KR101747103B1 (ko) 2017-06-14
KR101835648B1 (ko) 2018-03-07
RU2569157C2 (ru) 2015-11-20
MX2011014008A (es) 2012-06-01
KR20180110190A (ko) 2018-10-08
CN103833855A (zh) 2014-06-04
CA2766220A1 (en) 2010-12-29
JP7153048B2 (ja) 2022-10-13
WO2010151792A1 (en) 2010-12-29
US12157758B2 (en) 2024-12-03
RU2014114172A (ru) 2015-10-20
EP2445936A1 (en) 2012-05-02
MX342623B (es) 2016-10-06
TW201116625A (en) 2011-05-16
MX2019012601A (es) 2019-12-16
DK2975051T3 (da) 2021-04-26
JP2025026680A (ja) 2025-02-21
AU2015207952B2 (en) 2016-06-02
RU2015140911A (ru) 2017-03-30
MX2021009234A (es) 2022-06-14
KR101904065B1 (ko) 2018-10-04
PL2975051T3 (pl) 2021-09-20
EP2975051A1 (en) 2016-01-20
MY199658A (en) 2023-11-14
US20220024973A1 (en) 2022-01-27
JP2018035193A (ja) 2018-03-08
BRPI1015561A2 (pt) 2020-10-13
MY164121A (en) 2017-11-30
US20190031713A1 (en) 2019-01-31
AU2010265933B2 (en) 2015-05-14
SMT202100250T1 (it) 2021-07-12
HRP20210637T1 (hr) 2021-08-20
US20220389055A1 (en) 2022-12-08
CN102471378B (zh) 2014-04-02
JP6247673B2 (ja) 2017-12-13

Similar Documents

Publication Publication Date Title
US12157758B2 (en) Readily isolated bispecific antibodies with native immunoglobulin format
HK40064507A (en) Readily isolated bispecific antibodies with native immunoglobulin format
HK1219283B (en) Readily isolated bispecific antibodies with native immunoglobulin format